The CEO of South Africa’s second-largest generic drug manufacturer, Adcock Ingram‘s Andy Hall, has sought to allay fears that the government’s drive for universal health coverage poses a risk to the pharmaceutical sector, saying the reforms proposed under the National Health Insurance (NHI) Bill could boost drug sales. According to a Business Live report, this view is in contrast to the negative investor sentiment that greeted the release of the bill…..more
Health Systems Science (HSS), SA NHI
Adcock CEO upbeat about increased drug sales with NHI
